Vanessa Pataia,  —

Recent Posts

• FDA sees no need for DCCR advisory committee meeting
• Soleno’s DCCR under FDA priority review for hyperphagia in PWS
• CSTI-500 earns FDA’s rare pediatric disease designation for PWS
• Soleno files for US approval of DCCR for hyperphagia
• Seizures more likely in PWS caused by genetic deletion mutations
• PWS Awareness Month in May shines spotlight on the rare genetic disease
• Pitolisant enters pivotal Phase 3 testing for daytime sleepiness in PWS
• Pitolisant earns FDA orphan drug status ahead of Phase 3 trial
• Some PWS symptoms are more common with genetic deletion mutations: Study
• Tool to capture food-seeking behaviors in PWS clinical trials works in real life, too